CAS Number 1026511-90-9 ChemSpider 8152636 3D model (Jmol) Interactive image Molar mass 380.275 g/mol | PubChem CID 9977044 UNII S6NAA81PHK Formula C18H22BrNO3 | |
 | ||
Legal status DE: Anlage I (Controlled)
UK: Class A
US: Schedule I | ||
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor. Anecdotal reports from users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 12–16 hours.
Contents
The carbon-11 labeled version of this compound ([11C]Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen. As a 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [11C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. [11C]Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans.
Toxicity and harm potential
One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy.
25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram; Such a dose is 300× lower than the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans.
Several deaths have been attributed to its close analogue 25I-NBOMe.
Canada
As of October 31st, 2016; 25B-NBOMe is a controlled substance (Schedule III) in Canada.
Russia
Banned as a narcotic drug since May 5, 2015.
Sweden
In Sweden, the Riksdag added 25B-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of August 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25B-NBOMe 2-(4-bromo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.
United States
In November 2013, the U.S. Drug Enforcement Administration placed 25B-NBOMe (along with 25I-NBOMe and 25C-NBOMe) temporarily in Schedule I of the Controlled Substances Act, making it an illicit drug for two years. In November 2015, the temporary scheduling was extended for another year.
China
As of October 2015 25B-NBOMe is a controlled substance in China.
Czech Republic
25B-NBOMe is banned in the Czech Republic.